There are about 8616 clinical studies being (or have been) conducted in Netherlands. The country of the clinical trial is determined by the location of where the clinical research is being studied. Most studies are often held in multiple locations & countries.
To compare the efficacy and safety of FE 999049 (follitropin delta) and its personalized dosing algorithm in controlled ovarian stimulation for in vitro fertilization (IVF)/intracytoplasmic sperm injection (ICSI) using a long gonadotropin-releasing hormone (GnRH) agonist protocol versus a short GnRH antagonist protocol.
The objective of the study is to compare the outcomes after a surgical procedure with minimally invasive Ponto surgery (MIPS, test group) and tissue preservation surgery (control) for placing Oticon Medical Ponto implants and abutments.
The aim of this study is to gain insight in patients' experiences regarding do not resuscitate conversations and decisions. A multicentre flash mob investigation will be conducted in which data will be obtained over the course of two weeks using electronic questionnaires that patients will fill out. General demographic data and a brief quality of life assessment (EQ-5D) will be collected. Whether a DNR converstation has taken place will be noted, along with patients' experiences with this conversation. Lastly the patient will be asked about his/her expectations of survival after cardiopulmonary resuscitation.
This post-market follow-up study investigates improvement in clinical and radiological outcome after reversed total shoulder arthroplasty with the patient-specific Glenius Glenoid Reconstruction system
Right ventricular (RV) dysfunction in cardiac surgery is an independent risk factor for morbidity and mortality. Raising the systemic blood pressure with norepinephrine seems to have a positive influence on the right ventricular function in several animal studies. The current study is designed to evaluate the effect of a higher blood pressure on the RV function in post cardiac surgery patients.
The purpose of this Phase III study is to determine whether Eicosapentaenoic acid-free fatty acid is a safe and well tolerated treatment in reducing the number of polypectomies FAP patients with an APC gene mutation have over a 2 year treatment period and to assess the effect that this has on clinical disease progression.
This is an early-stage feasibility study. This study seeks to characterize the performance of the new electrode shock configuration with the S-ICD
The purpose of this study is to investigate how safe 2 different formulations (immediate-release (IR) and modified-release (MR) tablets) of the new compound GLPG3312 are and how well they are tolerated when they are administered to healthy volunteers. Immediate-release and modified-release tablets contain the same active ingredient, but the modified-release tablet is covered with a protective layer, so it will dissolve in the intestines and not in the stomach. GLPG3312 has not been administered to humans before. Next to assessing the safety and tolerability, the purpose of this study is to investigate how food affects how quickly and to what extent GLPG3312 in a modified release formulation is absorbed and eliminated from the body. In addition, the effect of GLPG3312 on the body will be investigated by evaluating the effect of GLPG3312 on markers of the immune response.
Type 2 diabetes mellitus (T2DM) and its associated cardiovascular comorbidities have developed into a leading cause of death in western countries. Medical and non-medical treatments have failed to counter this 'diabesity' epidemic, fostering the need for novel therapies. In this context, we have recently demonstrated robust improvements in insulin sensitivity in T2DM patients upon 10 days of mild cold acclimatisation, which proved to be primarily mediated through an increased skeletal muscle glucose uptake and occurred independent of improvements in classical regulatory pathways (i.e. insulin signalling or AMPK activation). Given this background, it was recently shown that skeletal muscle glucose uptake can also be mediated through an alternative novel pathway involving β2-adrenergic receptors, through activation of mTORC2. Thus, animal studies showed robust improvements in glucose homeostasis in diabetic rodents upon prolonged treatment with a low-dose of the selective β2-agonist clenbuterol. This project aims to investigate the human relevance of this novel β2-mTORC2 pathway and intents to investigate if prolonged supplementation with the selective β2-adrenergic agonist clenbuterol improves glucose disposal in healthy, lean male individuals. As such, this study serves as a proof-of-principle to identify if this novel pathway could potentially be used as a novel treatment target to improve glucose homeostasis T2DM patients.
This is a non-interventional/observational cohort of NSCLC unresectable stage III patients treated with durvalumab. The study will be carried out as a retrospective review of established medical records for a subset of unresectable stage III patients treated with durvalumab.